Dynacure Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
29
- Latest Deal Type
-
M&A
Dynacure General Information
Description
Operator of a clinical-stage drug development company created to improve the lives of patients with rare and orphan diseases. The company is developing an investigational antisense product candidate designed to reduce the expression of dynamin two protein for the treatment of myotubular and centronuclear myopathies, enabling doctors to build a complementary research portfolio for patients having other rare disorders, including its program for the treatment of hereditary spastic paraplegias caused by mutations in the gene.
Contact Information
Website
www.dynacure.comCorporate Office
- 850, Boulevard Sébastien Brant
- Illkirch-Graffenstaden
- 67400 Strasbourg
- France
Corporate Office
- 850, Boulevard Sébastien Brant
- Illkirch-Graffenstaden
- 67400 Strasbourg
- France
Dynacure Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Merger/Acquisition | 02-Mar-2023 | Completed | Generating Revenue | |||
| 9. IPO | 25-Jun-2021 | Cancelled | Clinical Trials - Phase 1 | |||
| 8. Later Stage VC (Series C) | 05-Nov-2020 | Completed | Clinical Trials - General | |||
| 7. Grant | 25-Apr-2019 | Completed | Clinical Trials - General | |||
| 6. Early Stage VC | 06-Jul-2018 | Completed | Clinical Trials - General | |||
| 5. Early Stage VC | 10-Nov-2017 | Completed | Clinical Trials - General | |||
| 4. Accelerator/Incubator | 01-Jan-2017 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC | 01-Nov-2016 | Completed | Clinical Trials - General | |||
| 2. Accelerator/Incubator | 01-Oct-2016 | $425K | $425K | Completed | Clinical Trials - General | |
| 1. University Spin-Out | 15-Dec-2015 | Completed | Startup |
Dynacure Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| C Shares | ||||||||
| B Shares | ||||||||
| Series A | 491,260 | $0.117608 | $18.82 | $18.82 | 1x | $18.82 | 9.87% | |
| Ordinary | 272,550 | $0.117608 | $14.11 | $14.11 | 1x | $14.11 | 5.47% |
Dynacure Comparisons
Industry
Financing
Details
Dynacure Competitors (6)
One of Dynacure’s 6 competitors is Sarepta Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Dyne Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| Arrowhead Pharmaceuticals | Corporation | Pasadena, CA | ||||
| Ionis Pharmaceuticals | Corporate Backed or Acquired | Carlsbad, CA | ||||
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA |
Dynacure Patents
Dynacure Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4311546-A1 | Combination therapy for myopathies | Inactive | 26-Jul-2022 | ||
| EP-4215614-A1 | Combination therapy for dystrophin-related diseases | Inactive | 24-Jan-2022 | ||
| WO-2018115477-A1 | Dynamin 2 inhibitor for the treatment of myotonic dystrophy | Inactive | 23-Dec-2016 | C12N15/113 |
Dynacure Signals
Dynacure Former Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Andera Partners | PE/Buyout | Minority | ||
| Bpifrance | Sovereign Wealth Fund | Minority | ||
| Conectus | Accelerator/Incubator | Minority | ||
| Government of Francaise | Government | |||
| Idinvest Partners | PE/Buyout | Minority |
Dynacure FAQs
-
When was Dynacure founded?
Dynacure was founded in 2015.
-
Where is Dynacure headquartered?
Dynacure is headquartered in Strasbourg, France.
-
What is the size of Dynacure?
Dynacure has 29 total employees.
-
What industry is Dynacure in?
Dynacure’s primary industry is Drug Discovery.
-
Is Dynacure a private or public company?
Dynacure is a Private company.
-
What is Dynacure’s current revenue?
The current revenue for Dynacure is .
-
How much funding has Dynacure raised over time?
Dynacure has raised $126M.
-
Who are Dynacure’s investors?
Andera Partners, Bpifrance, Conectus, Government of Francaise, and Idinvest Partners are 5 of 13 investors who have invested in Dynacure.
-
Who are Dynacure’s competitors?
Sarepta Therapeutics, Dyne Therapeutics, Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, and Dicerna Pharmaceuticals are some of the 6 competitors of Dynacure.
-
When was Dynacure acquired?
Dynacure was acquired on 02-Mar-2023.
-
Who acquired Dynacure?
Dynacure was acquired by Flamingo Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process